Main Article Content

Khalida Unar
Aiman Amur
Majeeda Ruk
Ayaz Ali Unar


Hemophilia, genetics, Pakistan. Treatments, causes


An inherited bleeding problem is hemophilia. Recombinant clotting factor VIII or factor IX and immunosuppressive drugs are used to treat hemophilia A or B to stop the development of alloantibodies and inhibitors. Treatment of hemophilia is a problem due to the formation of inhibitors to these factors. Patients with inhibitors are treated with activated recombinant factor VII and plasma-derived activated prothrombin complex concentrate. Treatment differs depending on the circumstance since bleeding is more likely to occur in cases of pregnancy, surgery, and cancer. The major topic of this study was to assess healthy persons' awareness of hemophilia and their familiarity with this condition from birth. 30 people from rural Sindh participated in a cross-sectional, random study. All participants were asked regular questions about their awareness of the illness, and SPSS software was used to analyze the data. There is currently no long-term or permanent treatment for hemophilia. Hemophilia may be temporarily cured by factor replacement. The direction of gene therapy or stem cell treatment, both of which are under development, may lead to a permanent cure. Previous research has shown that gene therapy seldom succeeds in curing patients for many months without the requirement for recombinant factor replenishment. To obtain a long-lasting and permanent cure for hemophilia, more adjustments to the treatment plan are necessary.

Abstract 116 | pdf Downloads 16


[1] Afshari, M. (2022). The impact of compounds from cigarette smoke on blood coagulation in vitro.
[2] Berntorp, E., Fischer, K., Hart, D. P., Mancuso, M. E., Stephensen, D., Shapiro, A. D., & Blanchette, V. (2021). Hemophilia. Nature Reviews Disease Primers, 7(1), 1-19.
[3] Bulut, Y., Sapru, A., & Roach, G. D. (2020). Hemostatic balance in pediatric acute liver failure: epidemiology of bleeding and thrombosis, physiology, and current strategies. Frontiers in Pediatrics, 8, 618119.
[4] Cattaneo, M. (2019). Inherited disorders of platelet function. In Platelets (pp. 877-904): Elsevier.
[5] Coppola, A., Franchini, M., Tripodi, A., Santoro, R. C., Castaman, G., Marino, R., . . . Contino, L. (2022). Acquired hemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding. Blood Transfusion, 20(3), 245.
[6] De la Corte-Rodriguez, H., Rodriguez-Merchan, E. C., Alvarez-Roman, M. T., & Jiménez-Yuste, V. (2021). Applying World Health Organization 2020 guidelines on physical activity and sedentary behavior to people with hemophilia. Expert Review of Hematology, 14(5), 429-436.
[7] Franjić, S. Intracerebral Hemorrhage.
[8] Garraud, O., Hamzeh-Cognasse, H., Chalayer, E., Duchez, A., Tardy, B., Oriol, P., . . . Cognasse, F. (2022). Platelet transfusion in adults: an update. Transfusion Clinique et Biologique.
[9] Ghetmiri, D. E., Cohen, M. J., & Menezes, A. A. (2021). Personalized modulation of coagulation factors using a thrombin dynamics model to treat trauma-induced coagulopathy. NPJ systems biology and applications, 7(1), 1-17.
[10] Hall, E. J., Carter, A. J., Bradbury, J., Barfield, D., & O’Neill, D. G. (2021). Proposing the VetCompass clinical grading tool for heat-related illness in dogs. Scientific Reports, 11(1), 1-11.
[11] Jain, K., & Ravikumar, P. (2020). Recent advances in treatments of cartilage regeneration for knee osteoarthritis. Journal of Drug Delivery Science and Technology, 60, 102014.
[12] Jankowska, K. I., Sauna, Z. E., & Atreya, C. D. (2020). Role of microRNAs in Hemophilia and Thrombosis in Humans. International Journal of Molecular Sciences, 21(10), 3598.
[13] Kato, T., Hanawa, T., Asou, M., Asakawa, T., Sakamaki, H., & Araki, M. (2021). Autoimmune factor V deficiency that took 16 years to diagnose due to pseudodeficiency of multiple coagulation factors. Case reports in medicine, 2021.
[14] Miller, C. H. (2021). The Clinical Genetics of Hemophilia B (Factor IX Deficiency). The Application of Clinical Genetics, 14, 445.
[15] Möller, K. Ä., Klein, S., Seeliger, F., Finn, A., Stenfors, C., & Svensson, C. I. (2019). Monosodium iodoacetate-induced monoarthritis develops differently in knee versus ankle joint in rats. Neurobiology of Pain, 6, 100036.
[16] Obeagu, E. I. (2022). Hemophilia B: A Review. Int. J. Curr. Res. Chem. Pharm. Sci, 9(1), 14-20.
[17] Perrin, G. Q., Herzog, R. W., & Markusic, D. M. (2019). Update on clinical gene therapy for hemophilia. Blood, The Journal of the American Society of Hematology, 133(5), 407-414.
[18] Peyvandi, F., Tavakkoli, F., Frame, D., Quinn, J., Kim, B., Lawal, A., . . . Wong, W. Y. (2019). Burden of mild hemophilia A: systematic literature review. Hemophilia, 25(5), 755-763.
[19] Ram Prakash, S. (2019). Clinical Profile of Hemophilia Patients and Assessment of their Quality of Life. Coimbatore Medical College, Coimbatore,
[20] Sanchez-Lara, P. A., Nathanson, J., & Valentino, L. A. (2022). Gene Therapy in Hemophilia: Latest Developments. In Advances in Hemophilia Treatment (pp. 155165): Springer.
[21] Sandilands, K., Williams, A., & Rylands, A. J. (2022). Carer burden in rare inherited diseases: a literature review and conceptual model. Orphanet Journal of Rare Diseases, 17(1), 1-20.
[22] Srivastava, A., Santagostino, E., Dougall, A., Kitchen, S., Sutherland, M., Pipe, S. W., . . . Windyga, J. (2020). WFH guidelines for the management of hemophilia. Hemophilia, 26, 1-158.
[23] Wilkins, R. A. (2021). Haemarthrosis of the ankle in hemophilia A and B: prevalence, impact and intervention. University of Leeds,
[24] Yousphi, A. S., Bakhtiar, A., Cheema, M. A., Nasim, S., & Ullah, W. (2019). Acquired hemophilia A: a rare but potentially fatal bleeding disorder. Cureus, 11(8).